乳腺癌靶向治疗进展.pptxVIP

刘健;早期乳腺癌靶向治疗进展;HERA研究: Her2阳性早期乳腺癌曲妥珠单抗辅助治疗10年随访结果 - 最终分析;eBC, early breast cancer; HR, hormone receptor; LVEF, left ventricular ejection fraction. * Stratification factors include HR status and endocrine therapy.;基线激素受体状态: 50% HR-阳性 50% HR-阴性 随机时年龄≤49岁患者: 52% 之前接受过蒽环类药物化疗的患者: 97% 2005年中期分析结果阳性, 共有884例观察组患者 (占观察组患者52%) 选择交叉至赫赛汀治疗组 这部分患者继续纳入观察组分析;Number at risk;CI, confidence interval; DFS, disease-free survival; HR, hazard ratio; MFU, median follow-up.;CI, confidence interval; HR, hazard ratio; ITT, intent-to-treat; OS, overall survival. * Three patients were excluded from the ITT populati